AVEO Pharmaceuticals, Inc.
AVEO
AVEO was delisted on the 19th of January, 2023.
48 hedge funds and large institutions have $28.5M invested in AVEO Pharmaceuticals, Inc. in 2016 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 12 increasing their positions, 3 reducing their positions, and 6 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 3
128% more capital invested
Capital invested by funds: $12.5M → $28.5M (+$16M)
117% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 6
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
17% more funds holding
Funds holding: 41 → 48 (+7)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$9.99M |
| 2 |
PA
Perceptive Advisors
New York
|
+$3M |
| 3 |
NLVP
New Leaf Venture Partners
New York
|
+$2.5M |
| 4 |
NC
Nexthera Capital
New York
|
+$500K |
| 5 |
Renaissance Technologies
New York
|
+$299K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCM
Gruss Capital Management
New York
|
-$1.44M |
| 2 |
SCM
Sarissa Capital Management
Greenwich,
Connecticut
|
-$303K |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$103K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$26.5K |
| 5 |
Morgan Stanley
New York
|
-$14.8K |
AVEO Hedge Fund Activity: Q2 2016 in Review
48 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in AVEO Pharmaceuticals, Inc. (AVEO) for Q2 2016, worth a combined $28.5M — up 128% from $12.5M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new AVEO positions and 6 closed out — a net gain of 7 holders — while 12 added to existing stakes and 3 trimmed.
The largest buyer was NEA Management Company, opening a new position worth an estimated $9.99M. The largest seller was Gruss Capital Management, exiting entirely with an estimated $1.44M sold.
- 48 institutional investors held AVEO Pharmaceuticals, Inc. (AVEO) as of Q2 2016, up from 41 in Q1 2016.
- Funds reported $28.5M of AVEO Pharmaceuticals, Inc. stock for Q2 2016, up 128% quarter-over-quarter.
- 13 funds opened new AVEO Pharmaceuticals, Inc. positions in Q2 2016 and 6 closed out, a net change of +7 holders.
- The largest AVEO Pharmaceuticals, Inc. buyer in Q2 2016 was NEA Management Company, an estimated $9.99M added.
- The largest AVEO Pharmaceuticals, Inc. seller in Q2 2016 was Gruss Capital Management, an estimated $1.44M sold.
Based on aggregated 13F filings for Q2 2016.